Darwin Wealth Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Darwin Wealth Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$24.2K	Buy	+48	New	+$25.4K	0.01%	474

Other funds holding MDGL

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Darwin Wealth Management's MDGL Position: Q3 2026 in Review

Darwin Wealth Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2026: 48 shares worth $24.2K. The stake represents 0.01% of the portfolio and ranks #474 among its holdings.

226 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

Darwin Wealth Management held 48 shares of Madrigal Pharmaceuticals worth $24.2K as of Q3 2026.
Madrigal Pharmaceuticals was a new Darwin Wealth Management position in Q3 2026.
Madrigal Pharmaceuticals made up 0.01% of Darwin Wealth Management's portfolio in Q3 2026, its #474 holding.
226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Darwin Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.